A Randomized, Comparative, Prospective Study of Daily Trimethoprim / Sulfamethoxazole (TMS) and Thrice-Weekly TMS for Prophylaxis Against PCP in HIV-Infected Patients
Pneumonia, Pneumocystis Carinii, HIV Infections
About this trial
This is an interventional treatment trial for Pneumonia, Pneumocystis Carinii focused on measuring Trimethoprim-Sulfamethoxazole Combination, Pneumonia, Pneumocystis carinii, Acquired Immunodeficiency Syndrome, AIDS-Related Complex, Sulfamethoxazole-Trimethoprim
Eligibility Criteria
Inclusion Criteria Patients must have: HIV infection. CD4 count <= 200 cells/mm3 OR a history of prior PCP. No active pneumocystosis. Patients or their guardians must sign informed consent. Pregnant patients are eligible at the clinician's discretion. Patients who do not meet required laboratory values may be eligible at the discretion of the clinician. Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: Known treatment-limiting reaction to sulfonamides or trimethoprim. Concurrent Medication: Excluded: Other PCP prophylaxis or medication with anti-PCP activity.
Sites / Locations
- Community Consortium of San Francisco
- Stanford Univ School of Medicine
- Denver CPCRA / Denver Public Hlth
- Wilmington Hosp / Med Ctr of Delaware
- Veterans Administration Med Ctr / Regional AIDS Program
- AIDS Research Consortium of Atlanta
- AIDS Research Alliance - Chicago
- Louisiana Comm AIDS Rsch Prog / Tulane Univ Med
- Baltimore Trials
- Univ of Maryland at Baltimore
- Comprehensive AIDS Alliance of Detroit
- Henry Ford Hosp
- Southern New Jersey AIDS Cln Trials / Dept of Med
- North Jersey Community Research Initiative
- Partners Research
- Univ Hosp / HIV - ID Clinic
- Bronx Lebanon Hosp Ctr
- Addiction Research and Treatment Corp
- Clinical Directors Network of Region II
- Harlem AIDS Treatment Group / Harlem Hosp Ctr
- Portland Veterans Adm Med Ctr / Rsch & Education Grp
- Philadelphia FIGHT
- Richmond AIDS Consortium
- Univ of Washington / Pacific Med Ctr